Dr. Sonal Kumar, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 275
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Washington University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 263182 · MA license 239755 -
Internal Medicine Physician
MO license 2008030948
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 275
- Services billed
- 563
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 151 | 121 |
| Measurement of liver stiffness | 147 | 147 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 33 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | 28 |
| Biopsy of large bowel using a flexible endoscope | 26 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 15 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vemlidy (tenofovir alafenamide) | 17 |
| Rezdiffra (resmetirom) | 15 |
| Ursodiol Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 250 payments worth $367,785 in total to this clinician.
| Novo Nordisk Inc | $111,103 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $78,351 |
| Madrigal Pharmaceuticals | $66,219 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49,304 |
| Gilead Sciences, Inc. | $37,504 |
| GlaxoSmithKline, LLC. | $13,208 |
| Novo Nordisk As | $8,290 |
| Intercept Pharmaceuticals, Inc. | $2,480 |
| Compensation for services other than consulting (speaking, faculty) | $176,158 |
|---|---|
| Consulting Fee | $155,619 |
| Travel and Lodging | $27,266 |
| Food and Beverage | $8,741 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Consulting Fee | $17,765 |
| Novo Nordisk Inc Oct 27, 2025 | Consulting Fee Multiple Therapeutic Areas | $15,504 |
| Novo Nordisk Inc Jun 24, 2025 | Consulting Fee Multiple Therapeutic Areas | $14,719 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $13,440 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee | $12,495 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,912 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 11, 2025 | Consulting Fee | $11,495 |
| Ipsen Biopharmaceuticals, Inc Apr 2, 2025 | Consulting Fee IQIRVO · Rare Disease | $10,693 |
| Ipsen Biopharmaceuticals, Inc Jan 6, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $10,450 |
| Novo Nordisk Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) Multiple Therapeutic Areas | $9,616 |
All 137 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Dec 30, 2025 | Consulting Fee | $3,525 |
| Gilead Sciences, Inc. Dec 18, 2025 | Consulting FeeCompany’s description;4285651;GTF;11163810 | $2,040 |
| Gilead Sciences, Inc. Dec 18, 2025 | Travel and Lodging travel to Washington, DC Company’s description;4285643;GTF;11163810 | $460 |
| Madrigal Pharmaceuticals Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Madrigal Pharmaceuticals Dec 15, 2025 | Consulting Fee | $1,058 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 11, 2025 | Consulting Fee | $11,495 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 11, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $140 |
| Novo Nordisk Inc Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $1,963 |
| Novo Nordisk Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,103 |
| Novo Nordisk Inc Nov 19, 2025 | Consulting Fee Multiple Therapeutic Areas | $3,611 |
| Novo Nordisk Inc Nov 19, 2025 | Travel and Lodging Wegovy · Obesity · travel to Great Neck, NY · in-kind | $246 |
| Madrigal Pharmaceuticals Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Nov 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to NEW YORK, NY | $68.32 |
| Madrigal Pharmaceuticals Nov 17, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $647 |
| Madrigal Pharmaceuticals Nov 17, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $328 |
| Madrigal Pharmaceuticals Nov 17, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $324 |
| Madrigal Pharmaceuticals Nov 17, 2025 | Travel and Lodging travel to BOSTON, MA | $148 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $8,046 |
| Novo Nordisk Inc Nov 13, 2025 | Travel and Lodging Wegovy · Obesity · travel to Albany, NY · in-kind | $1,202 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $188 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 7, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $150 |
| Novo Nordisk Inc Nov 3, 2025 | Consulting Fee Multiple Therapeutic Areas | $3,611 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 3, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $1,092 |
| Novo Nordisk Inc Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,084 |
| Novo Nordisk Inc Oct 30, 2025 | Travel and Lodging Wegovy · Obesity · travel to New Rochelle, NY · in-kind | $164 |
| Novo Nordisk Inc Oct 27, 2025 | Consulting Fee Multiple Therapeutic Areas | $15,504 |
| Novo Nordisk Inc Oct 27, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Chandler, AZ · in-kind | $790 |
| Novo Nordisk Inc Oct 27, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Chandler, AZ · in-kind | $659 |
| Novo Nordisk Inc Oct 27, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Chandler, AZ · in-kind | $143 |
| Novo Nordisk Inc Oct 26, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,570 |
| Gilead Sciences, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4249417;GTF;11163810 | $600 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Consulting Fee | $17,765 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $140 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,912 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $663 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $529 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $221 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 9, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $194 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 9, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $96.60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 8, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $326 |
| Ipsen Biopharmaceuticals, Inc Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $6,175 |
| Ipsen Biopharmaceuticals, Inc Oct 2, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Boston, MA · in-kind | $791 |
| Ipsen Biopharmaceuticals, Inc Oct 2, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Boston, MA · in-kind | $441 |
| Gilead Sciences, Inc. Oct 2, 2025 | Travel and Lodging Epclusa · HCV · travel to New York, NY · in-kind Company’s description;4265637;AHM;11163810 | $115 |
| Ipsen Biopharmaceuticals, Inc Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,850 |
| Madrigal Pharmaceuticals Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Sep 30, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to NEW YORK, NY | $37.09 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 29, 2025 | Consulting Fee | $3,919 |
| Madrigal Pharmaceuticals Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,740 |
| Madrigal Pharmaceuticals Sep 19, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to BROOKLYN, NY | $121 |
| Gilead Sciences, Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4264916;AHM;11163810 | $3,790 |
| Ipsen Biopharmaceuticals, Inc Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $6,175 |
| Ipsen Biopharmaceuticals, Inc Sep 12, 2025 | Consulting Fee IQIRVO · Rare Disease | $6,650 |
| Novo Nordisk Inc Sep 4, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,963 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 3, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $555 |
| Madrigal Pharmaceuticals Sep 2, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $8,989 |
| Novo Nordisk Inc Sep 1, 2025 | Consulting Fee Multiple Therapeutic Areas | $4,514 |
| Gilead Sciences, Inc. Aug 27, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to New York, NY · in-kind Company’s description;4126610;AHM;11163810 | $81.65 |
| Ipsen Biopharmaceuticals, Inc Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,836 |
| Madrigal Pharmaceuticals Aug 22, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL | $76.08 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $477 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $250 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $221 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL | $64.50 |
| Gilead Sciences, Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4118868;AHM;11163810 | $3,030 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $292 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX | $114 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $103 |
| GlaxoSmithKline, LLC. Jul 14, 2025 | Travel and Lodging travel to Raleigh, NC · in-kind | $272 |
| GlaxoSmithKline, LLC. Jul 14, 2025 | Travel and Lodging travel to Newark, NJ · in-kind | $31.41 |
| Novo Nordisk Inc Jun 24, 2025 | Consulting Fee Multiple Therapeutic Areas | $14,719 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $685 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $646 |
| Madrigal Pharmaceuticals Jun 21, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,993 |
| Madrigal Pharmaceuticals Jun 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to ACME, MI · in-kind | $773 |
| Madrigal Pharmaceuticals Jun 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to ACME, MI · in-kind | $426 |
| Madrigal Pharmaceuticals Jun 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to ACME, MI | $169 |
| Gilead Sciences, Inc. Jun 18, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4110473;AHM;11163810 | $140 |
| Gilead Sciences, Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4128915;AHM;11163810 | $5,150 |
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,850 |
| Gilead Sciences, Inc. Jun 13, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4328104;AHM;11163810 | $654 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 13, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $209 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4128746;AHM;11163810 | $441 |
| Ipsen Biopharmaceuticals, Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,225 |
| Gilead Sciences, Inc. Jun 5, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4122249;AHM;11163810 | $420 |
| Madrigal Pharmaceuticals Jun 3, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jun 3, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to NEW YORK, NY | $52.64 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $13,440 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $809 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee | $12,495 |
| Madrigal Pharmaceuticals May 29, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Merck Sharp & Dohme LLC May 21, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $750 |
| Novo Nordisk Inc May 16, 2025 | Compensation for services other than consulting (speaking, faculty) Multiple Therapeutic Areas | $9,224 |
| Novo Nordisk Inc May 16, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Orlando, FL · in-kind | $599 |
| Novo Nordisk Inc May 16, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Orlando, FL · in-kind | $331 |
| Novo Nordisk Inc May 16, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Orlando, FL · in-kind | $135 |
| Gilead Sciences, Inc. May 5, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Manchester, NH · in-kind Company’s description;4118512;AHM;11163810 | $131 |
| Intercept Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $620 |
| Intercept Pharmaceuticals, Inc. Apr 27, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $1,860 |
| GlaxoSmithKline, LLC. Apr 11, 2025 | Travel and Lodging travel to Durham, NC | $518 |
| GlaxoSmithKline, LLC. Apr 11, 2025 | Travel and Lodging travel to Durham, NC | $416 |
| Gilead Sciences, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4114089;AHM;11163810 | $3,790 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee | $4,000 |
| Ipsen Biopharmaceuticals, Inc Apr 2, 2025 | Consulting Fee IQIRVO · Rare Disease | $10,693 |
| Gilead Sciences, Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4114959;AHM;11163810 | $3,030 |
| Novo Nordisk As Mar 26, 2025 | Consulting Fee Multiple Therapeutic Areas | $4,906 |
| Novo Nordisk As Mar 26, 2025 | Consulting Fee Multiple Therapeutic Areas | $2,355 |
| Ipsen Biopharmaceuticals, Inc Mar 26, 2025 | Consulting Fee IQIRVO · Rare Disease | $1,262 |
| Novo Nordisk As Mar 26, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Montreal, Canada · in-kind | $712 |
| Novo Nordisk As Mar 26, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Montreal, Canada · in-kind | $317 |
| Madrigal Pharmaceuticals Mar 19, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $4,230 |
| Gilead Sciences, Inc. Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4114342;AHM;11163810 | $3,940 |
| Gilead Sciences, Inc. Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4110545;AHM;11163810 | $5,150 |
| Gilead Sciences, Inc. Mar 6, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Manchester, NH · in-kind Company’s description;4113741;AHM;11163810 | $649 |
| Gilead Sciences, Inc. Mar 6, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4123034;AHM;11163810 | $508 |
| Gilead Sciences, Inc. Mar 5, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Boston, MA · in-kind Company’s description;4098536;AHM;11163810 | $1,357 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026754;GTF;11163810 | $569 |
| Madrigal Pharmaceuticals Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Feb 26, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to FORT LEE, NJ | $160 |
| GlaxoSmithKline, LLC. Feb 10, 2025 | Consulting Fee | $400 |
| Novo Nordisk Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) Multiple Therapeutic Areas | $9,616 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $3,800 |
| Novo Nordisk Inc Feb 8, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Fort Lauderdale, FL · in-kind | $518 |
| Novo Nordisk Inc Feb 8, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Fort Lauderdale, FL · in-kind | $318 |
| Novo Nordisk Inc Feb 8, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Fort Lauderdale, FL · in-kind | $211 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $71.88 |
| Madrigal Pharmaceuticals Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| GlaxoSmithKline, LLC. Jan 28, 2025 | Consulting Fee | $3,600 |
| GlaxoSmithKline, LLC. Jan 28, 2025 | Consulting Fee | $3,200 |
| GlaxoSmithKline, LLC. Jan 17, 2025 | Travel and Lodging travel to Farmingdale, NY | $692 |
| Novo Nordisk Inc Jan 8, 2025 | Consulting Fee Multiple Therapeutic Areas | $4,318 |
| Ipsen Biopharmaceuticals, Inc Jan 6, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $10,450 |
| Ipsen Biopharmaceuticals, Inc Jan 6, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Phoenix, AZ · in-kind | $224 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $208,449 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)…
Gilead Sciences, Inc. - An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gilead Sciences, Inc. - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.